Healthcare provider profile · identity verified

Sarah K Marcoe, MD

Family Practice · KIMBERLY, WI · NPI 1306886601

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	518	138
Omeprazole	Omeprazole	269	68
Lisinopril	Lisinopril	258	63
Amlodipine Besylate	Amlodipine Besylate	249	66
Levothyroxine Sodium	Levothyroxine Sodium	234	56
Metformin Hcl Er	Metformin Hcl	170	46
Gabapentin	Gabapentin	121	33
Hydrochlorothiazide	Hydrochlorothiazide	119	37
Escitalopram Oxalate	Escitalopram Oxalate	118	30
Eliquis	Apixaban	116	23
Metoprolol Succinate	Metoprolol Succinate	105	32
Furosemide	Furosemide	102	28
Losartan Potassium	Losartan Potassium	100	31
Sertraline Hcl	Sertraline Hcl	97	19
Rosuvastatin Calcium	Rosuvastatin Calcium	85	27
Metoprolol Tartrate	Metoprolol Tartrate	81	17
Trazodone Hcl	Trazodone Hcl	80	24
Pantoprazole Sodium	Pantoprazole Sodium	79	19
Duloxetine Hcl	Duloxetine Hcl	77	17
Bupropion Xl	Bupropion Hcl	74	16
Allopurinol	Allopurinol	66	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	64	17
Simvastatin	Simvastatin	59	17
Famotidine	Famotidine	57	suppressed
Carvedilol	Carvedilol	55	15
Albuterol Sulfate Hfa	Albuterol Sulfate	52	32
Fluticasone Propionate	Fluticasone Propionate	47	17
Potassium Chloride	Potassium Chloride	47	14
Valsartan	Valsartan	46	13
Mirtazapine	Mirtazapine	44	suppressed
Warfarin Sodium	Warfarin Sodium	43	suppressed
Pravastatin Sodium	Pravastatin Sodium	42	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	39	13
Montelukast Sodium	Montelukast Sodium	39	suppressed
Xarelto	Rivaroxaban	37	suppressed
Ezetimibe	Ezetimibe	36	suppressed
Pregabalin	Pregabalin	36	suppressed
Buspirone Hcl	Buspirone Hcl	35	suppressed
Memantine Hcl	Memantine Hcl	31	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Atenolol	Atenolol	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Myrbetriq	Mirabegron	29	suppressed
Cephalexin	Cephalexin	28	26
Ozempic	Semaglutide	27	suppressed
Spironolactone	Spironolactone	26	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	26	suppressed
Jardiance	Empagliflozin	24	suppressed
Baclofen	Baclofen	22	suppressed
Trulicity	Dulaglutide	22	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Prednisone	Prednisone	21	20
Alendronate Sodium	Alendronate Sodium	19	suppressed
Aripiprazole	Aripiprazole	19	suppressed
Methimazole	Methimazole	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Arnuity Ellipta	Fluticasone Furoate	17	suppressed
Celecoxib	Celecoxib	17	suppressed
Glipizide	Glipizide	17	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	suppressed
Lorazepam	Lorazepam	17	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	17	suppressed
Meloxicam	Meloxicam	15	suppressed
Metformin Hcl	Metformin Hcl	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Fesoterodine Fumarate Er	Fesoterodine Fumarate	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	11
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error